KRISTALIN ACTION PLUS

Основна информация

  • Търговско наименование:
  • KRISTALIN ACTION PLUS
  • Използвай за:
  • Хората
  • Вид на лекарството:
  • Медицински устройство

Документи

Локализация

  • Предлага се в:
  • KRISTALIN ACTION PLUS
    България
  • Език:
  • български

Друга информация

Състояние

  • Източник:
  • Ecolab
  • Номер на разрешението:
  • 109999E
  • Последна актуализация:
  • 12-03-2018

5-6-2018

FDA takes action against 53 websites marketing unapproved opioids as part of a comprehensive effort to target illegal online sales

FDA takes action against 53 websites marketing unapproved opioids as part of a comprehensive effort to target illegal online sales

FDA announced that it has warned nine online networks, operating a total of 53 websites, that they must stop illegally marketing potentially dangerous, unapproved and misbranded versions of opioid medications, including tramadol and oxycodone.

FDA - U.S. Food and Drug Administration

1-6-2018

Important sunscreen safety tips for Canadians

Important sunscreen safety tips for Canadians

Health Canada is in the process of reviewing the safety of various sunscreen products and will share the results in the coming weeks. The Department will take immediate action and inform Canadians should a safety concern be identified with any sunscreen product sold in Canada.

Health Canada

31-5-2018

Abbott Implements Corrective Action for Heartmate 3 Heart Pump

Abbott Implements Corrective Action for Heartmate 3 Heart Pump

Abbott is communicating to physicians about a field corrective action related to the HeartMate 3™ Left Ventricular Assist Device (LVAD). Abbott notified physicians and global regulatory bodies on April 5, 2018, that outflow graft twisting could occur post-implant in the HeartMate 3 LVAD, resulting in a persistent low flow alarm that may signal a potential safety risk to patients, such as low blood flow or clotting.

FDA - U.S. Food and Drug Administration

23-5-2018

FDA takes action against the use of OTC benzocaine teething products due to serious safety risk, lack of benefit

FDA takes action against the use of OTC benzocaine teething products due to serious safety risk, lack of benefit

OTC oral health products containing benzocaine for the temporary relief of sore gums due to teething in infants or children should no longer be marketed. FDA is asking companies to stop selling these products for such use and requesting that companies add new warnings to all other benzocaine oral health products to describe certain serious risks.

FDA - U.S. Food and Drug Administration

22-5-2018

Risk of serious and potentially fatal blood disorder prompts FDA action on oral over-the-counter benzocaine products used for teething and mouth pain and prescription local anesthetics

Risk of serious and potentially fatal blood disorder prompts FDA action on oral over-the-counter benzocaine products used for teething and mouth pain and prescription local anesthetics

FDA is taking safety actions regarding over-the-counter benzocaine oral drug products and prescription local anesthetics.

FDA - U.S. Food and Drug Administration

1-5-2018

FDA, FTC take action against companies misleading kids with e-liquids that resemble children’s juice boxes, candies and cookies

FDA, FTC take action against companies misleading kids with e-liquids that resemble children’s juice boxes, candies and cookies

FDA, FTC take action against companies misleading kids with e-liquids that resemble children’s juice boxes, candies and cookies

FDA - U.S. Food and Drug Administration

12-4-2018

Z-classification revoked for S-classified medicinal products, which are foreseen to maintain their S-classified status

Z-classification revoked for S-classified medicinal products, which are foreseen to maintain their S-classified status

The Agency intends to revoke Z-classification of those S-classified medicinal products, which are foreseen to maintain their S-classified status. In case a marketing authorisation holder has any comments on the Agency´s planned action, such comments must be submitted before 16 April 2018.

IMA - Icelandic Medicines Agency

15-11-2017

Infections associated with heater-cooler devices

Infections associated with heater-cooler devices

Update to statement regarding heater-cooler devices following recall action and suspension of LivaNova 3T heater-coolers

Therapeutic Goods Administration - Australia

3-2-2015

New director at the DHMA

New director at the DHMA

On 1 February 2015, Anne-Marie Vangsted, Acting Head of Division, took up the position as Director with responsibility for supervision at the Danish Health and Medicines Authority. The new position as director was created as part of our action plan aimed at modernising the supervisory function, in which Anne-Marie Vangsted has played a key role since we presented the plan on 15 September 2014.

Danish Medicines Agency

7-7-2014

Monitoring of medicines for births

Monitoring of medicines for births

The Danish Health and Medicines Authority has prepared a midterm review of the activities in the action plan for Danish regions' use of medicines for the induction of labour. The action plan was launched in the autumn of 2013 following a public debate about the use of these medicines, and it should be completed by the end of 2015.

Danish Medicines Agency